Pfizer lands in Paris the week of the ASCO cancer conference

Pfizer flew from São Paulo to Paris-Le Bourget on May 22, 2026, aboard its Gulfstream G650ER (N6CP), completing a 9-hour-44-minute transatlantic crossing. The aircraft, part of Pfizer's all-Gulfstream fleet, touched down in the French capital just before noon local time.

The same week, Pfizer is preparing to present more than 40 abstracts at the American Society of Clinical Oncology (ASCO) annual meeting, which runs May 29 through June 2 in Chicago, per a company press release on pfizer.com. The data includes late-breaking results from the CROWN study of Lorbrena in lung cancer and the BREAKWATER trial of Braftovi in colorectal cancer. While the meeting itself is in the United States, Paris serves as a logical European hub for pre-conference meetings with investigators, regulators, and partners — a pattern Pfizer's flight history supports.

The G650ER's itinerary over the past week shows a clear European-to-Latin America-to-Europe loop: from Paris to Mexico City on May 18, then to São Paulo on May 20, and back to Paris on May 22. This suggests Pfizer's executive team conducted a series of in-person regional business reviews or regulatory discussions before regrouping in Europe ahead of the oncology showcase.